Kornimate/medical-research-clean huggingface dataset:
safety and effectiveness of a novel enteral feeding system: prospective study.

Conditions: Enteral Feeding

Summary: the goal of this interventional study is to obtain information on the safety and effectiveness of a novel enteral feeding system in adult users requiring at least a portion of their nutritional intake via enteral feeding. the main questions it aims to answer are: * can the device be used safely and effectively? * does use of the device impact on patient's quality of life? participants will use mobility+ enteral feeding system as their enteral feeding method for the duration of the study and will record their experiences.

the study will allow 25 participants to use the mobility+ system for their feeding sessions over the course of 14 consecutive days, following an initial 7-day period where participants have time to trial and get used to the new system. participants' homes are the setting for the 21-day study duration.

Eligibility criteria:
inclusion criteria: * participants with gastrostomy (g) tube or jejunostomy (j) tubes * participant must require enteral tube feeding every day, as determined at the time of study enrolment * participant must use commercially available enteral formula with standard enteral feeding system(s) (gravity bag, bolus, pump or combination(s)), for some or all of their tube feeds, for daytime or day and night-time feeding * participant must be en dependent i.e., 500 ml minimum daily feed intake from en * participants must be able to swap from current system to mobility+ for a minimum of two daily feeds per day for duration of study (study days 1 -14) * participant must be \>= 18 to reflect the subset of the intended use population being evaluated * participant must be willing to participate in the study and provide consent). * participants must have been on an enteral feeding regime for a minimum of 10 weeks * participants clinical functional capacity is adequate as determined by operator clinical judgement, to enable them to participate fully in the study * participants are suitable candidates for using mobility+ as determined by operator clinical judgement on participant enteral feeding needs (as per prescription) and alignment with mobility+ flow rate guide exclusion criteria: * participants who do not use commercially available enteral formula for some or all their formula needs * participants unable/unwilling to provide consent * participants whose enteral feeding needs do not match the offering of the mobility+, as determined by operator clinical judgement * participants who have inadequate clinical functional capacity, as determined by operator clinical judgement to participate fully in the study e.g. neuromuscular or neurodegenerative disorders, or developmental delay * participants with very limited mobility, as determined by operator clinical opinion

Keywords: enteral feeding mobility quality of life elastomeric
safety and efficacy of diverse mesenchymal stem cells transplantation for liver failure

Conditions: Liver Failure

Summary: hbv-related liver failure (hbv-lf), a dramatic clinical syndrome, is characterized with massive necrosis of liver cells. liver transplantation might be the most effective therapy for hbv-lf. however, there are a lot of problems such as lack of donors, surgical complications, transplant rejection, and high cost, which could limit the application of liver transplantation. it is demonstrated that mesenchymal stem cells could directionally differentiate into hepatocytes and cholangiocytes in injured liver, as well as reduce inflammation of the liver by immune regulation. in this study, we assess the safety and efficacy of human bone marrow and umbilical cord mesenchymal stem cells transplantation for patients with hbv-lf.


Eligibility criteria:
inclusion criteria: * aged 18-65 years * liver failure * negative pregnancy test (female patients in fertile age) * written consent * hbsag positive * tb≥171 μmol/l or ascend ≥17.1 μmol/l/per day, * inr≥1.5 or 20%\<pta≤40% * 17≤meld score≤30 exclusion criteria: * hepatocellular carcinoma or other malignancies * severe problems in other vital organs(e.g.the heart,renal or lungs) * pregnant or lactating women * severe bacteria infection * anticipated with difficulty of follow-up observation * liver failure caused by other reasons, such as autoimmune diseases, alcohol, drug and so on * other candidates who are judged to be not applicable to this study by doctors
imt outcomes in sufferers of severe walking disabilities and intensive care unit acquired weakness

Conditions: Intensive Care Unit Acquired Weakness

Summary: intensive care unit-acquired weakness (icu-acquired weakness) may be caused by a variety of different causes. several studies have shown that icu-acquired weakness occurs in up to 30% of critically ill patients. it affects daily activities, walking, and functional performance

forty icu-acquired weakness elderly patients will be randomly assigned to group a and group b, 20 elderly for each. both groups will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). group a only will receive 3-set imt (two sessions daily via threshold imt, the set contain 10 repetitions) 5 times weekly. the study duration will be 1 month.

Eligibility criteria:
inclusion criteria: * sufferers with intensive care unit acquired weakness * older sufferers patients with severe walking disability detected by modified functional ambulation category test, exclusion criteria: * lower limb amputations * orthopedic or spinal disc disorders
molecularly tailored therapy for patients with metastatic cancer of the esophagus and stomach

Conditions: Esophageal Cancer; Gastric Cancer

Summary: the purpose of this study is to determine whether molecular profile-directed therapy (otherwise known as personalized treatment) can improve the effectiveness of standard chemotherapy combinations for patients with esophagogastric adenocarcinoma. a series of tests will be performed on a sample of tumor; based on the results of these tests, a patient will be assigned to a chemotherapy treatment.


Eligibility criteria:
inclusion criteria: * advanced, measurable metastatic esophagogastric adenocarcinoma by recist criteria * patients who have had surgery or radiotherapy with or without neoadjuvant or adjuvant chemotherapy (the wash-out period will be at least 1 month) * patients who are not eligible for resection and are chemotherapy naïve * patients with her2(-) status * patients who have tumor deposit(s) that are easily accessible by ultrasound or ct guidance * patients must have adequate organ function * patients must provide written informed consent exclusion criteria: * active concurrent malignancy, other than superficial, non-squamous cell carcinoma of the skin or uterine cervix, within the past three years * ecog performance status worse than 2 * prior oral or intravenous chemotherapy for metastatic disease * patients with comorbidities that prevent them from being able to receive the chemotherapy regimen * cardiac ejection fraction 45% or greater
use of omegaven fish oil emulsion for parenteral nutrition associated liver disease in infants and children

Conditions: Cholestasis

Summary: use of a fish oil emulsion to decrease liver disease due to long term intravenous nutrition.

unlike conventional intravenous fat emulsions, omegaven™ is comprised solely of fish oils containing primarily omega-3 fatty acids. animal studies have shown that iv fat emulsions such as fish oil that are high in eicosapentaenic and docosahexaenoic acids reduce impairment of bile flow as seen in cholestasis caused by conventional fat emulsions. it is thought that by administering omegaven™ in place of conventional phytosterol/soybean fat emulsions, cholestasis may be prevented or reversed, and patients will be able to be maintained on adequate pn for growth until they are able to ingest adequate nutrition enterally. ongoing studies are addressing safety and efficacy of omegaven™ in the pediatric population. in this trial, infants and children with parenteral nutrition associated liver disease will receive omegaven™ as compassionate use to potentially prevent progression of disease. safety and efficacy are monitored.

Eligibility criteria:
inclusion criteria: * direct bilirubin \> 2 mg/dl x2 consecutive * parenteral nutrition dependent, expected to continue for at least another 30 days from the first day * patient must have utilized standard therapies to prevent the progression of liver disease exclusion criteria: * other primary cause of liver disease not parenteral nutrition-associated * weight \<3 kg * infant or child enrolled in other clinical trial involving an investigational agent

Keywords: short bowel syndrome parenteral nutrition associated liver disease pediatric
body mass index and audiology function

Conditions: Hearing Loss

Summary: obesity may directly or indirectly lead to hearing loss

obesity is measured by body mass index.it is calculated by dividing a person's weight in kilograms by the square of height in meters. for children and adolescent. overweight is defined as body mass index is \<85th percentile \<95th percentile but obesity is defined as body mass index at or above the 95th percentile for children and teens of the same age and sex the increasing in body mass index mass may affect auditory function directly as adipose tissue secretes hormones and cytokines, proinflammatory cytokines lead to release of obesity-induced inflammation which may directly contribute to end-organ damage also, adiponectin, which is thought to have anti-inflammatory and antiatherogenic effects, and associated with favorable lipoprotein profile, independent of bmi and insulin resistance, low plasma concentrations of adiponectin have been associated with obesity in children. in adults, low level of adiponectin has been associated with elevated high-frequency thresholds. indirectly, by obesity comorbidities including hypertension, type 2 diabetes mellitus, dyslipidemia , metabolic syndrome and cardiovascular diseases

Eligibility criteria:
inclusion criteria: it will include 50 subjects whose: * age ranges from 10 to 40 years old. * body mass index more than the 85th percentile. * male and female will be included exclusion criteria: * external or middle ear disease that causes conductive hearing loss such as otitis media, otomycosis, perforated drum, tumors, dislocation of the ossicles. * high environmental noise exposure which causes acoustic trauma such as exploration, fire shots and noise in industries. * ototoxic drug intake such as aspirin, aminoglycosides, erythromycin, vancomycin streptomycin, kanamycin, neomycin, gentamycin, tobramycin, lasix, cisplatin, nitrogen mustard, and vincristine, and quinine. * major neurological or psychiatric diseases brain tumor, vestibular schwannoma, stroke, acoustic neuroma, encephalitis, meningitis, and depression.

Keywords: obesity
an observational study validating a score that quantifies the therapeutic response to treatment with norditropin®

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency

Summary: this observational study is conducted in europe. the aim of this observational study is to investigate the changes in a score (get-score) which includes quality of life, body composition and cholesterol metabolism in patients on growth hormone treatment. the get score stands for: growth hormone deficiency and efficacy of treatment, and is a quantitative measurement of the efficacy of the treatment with growth hormone in adults.


Eligibility criteria:
inclusion criteria: * severe acquired growth hormone deficiency * no treatment with somatropin in the last 24 months before study participation * written informed consent exclusion criteria: * contraindications for the treatment with somatropin
patient reported outcomes for opioid use disorder

Conditions: Opioid-use Disorder; Overdose of Opiate; Patient Participation

Summary: the goal of the project is to build a clinical data research infrastructure that will begin to enhance capacity to use electronic health record (ehr) data and patient reported outcomes measures (pros) to conduct opioid related research in emergency departments (eds). 200 adult patients with a history of non-medical opioid use, opioid use disorder, or acute opioid overdose will be enrolled and will be asked to complete three pro surveys (baseline, 3 days post ed discharge, and 30 days post discharge).


Eligibility criteria:
inclusion criteria: * adult patient presenting to the yale new haven hospital york street campus emergency department * history of opioid use disorder or non-medical use of opioids, as measured by screening assessment or receiving treatment for opioid overdose * willingness and ability to complete electronic surveys via a smartphone or computer exclusion criteria: * \<18 years of age * inability to communicate in english * inability to provide consent (for example, due to psychosis, intoxication, severe mental illness or other reason) * transfer from the ed for psychiatric evaluation

Keywords: patient reported outcomes clinical data research electronic health records
effectiveness of vr exercise intervention on functional fitness and quality of life among elderly

Conditions: Health Promotion

Summary: the aim of this study is to determine the effect of virtual reality-based exercise on the intervention and follow-up retention of functional fitness and quality of life among older adults.

in a worldwide survey of fitness trends last 2021, virtual reality (vr) training recently took the top 10 spots. in fact, only a few studies were conducted on the retention of functional fitness and quality of life among older people. the main goal of this study was to assess the effects of virtual reality exercise on the functional fitness and quality of life of older adults after 12 weeks of intervention and another 12 weeks of follow-up.

Eligibility criteria:
inclusion criteria: 1. aged ≥ 65, 2. are able to perform daily activities, 3. with no past or current history of medical situations found in the physical activity readiness questionnaire (par-q). exclusion criteria: 1. being less than 65 years of age, 2. being unfit to participate in the study as revealed by the par-q.
evaluation of the use of resources and costs

Conditions: Surgical Incision

Summary: evaluation of the use of resources and costs with o-arm in deep brain stimulation (dbs) surgeries and complex back surgeries

to measure the use of health resources in application a (with dbs) and in application b (vertebral fusions), in patients in the intervention group with o-arm and in the control group (usual care without o-arm) with the cost in each phase (pre-surgical, surgical, post-surgical and follow-up at 6 months (raquis) and at 12 months (dbs))

Eligibility criteria:
inclusion criteria: * patients aged ≥18 years. * signed informed consent. * patients with indication for dbs surgery for movement disorders, epilepsy and obsessive-compulsive disorder, or for cervical, dorsal or lumbar fusion surgery levels 1,2 and 3 in a degenerative disease exclusion criteria: * patients who have had pediatric instrumented surgery. * patients in which the pedicle screws are inserted for neoplasia or other disease.

Keywords: deep brain surgery and complex back surgery
acute effect of cpap on weight in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the effect of cpap on weight and fluid homeostasis will be assessed. obstructive sleep apnea treatment-naive subjects will randomized to cpap and control groups. weight change, and changes in overnight urinary volume, intra and extracelullar volume, plasmatic b-type natriuretic peptide (bnp) and antidiuretic hormone (adh) and urinary osmolality will be compared between groups.

there is a bidirectional relationship between obstructive sleep apnea (osa) and obesity. although obesity can lead to osa, patients with osa are more likely to gain weight. the mechanisms that lead to weight gain during the treatment of osa are not known. some evidence supports the hypothesis that fluid accumulation could be a possible explanation for weight gain after treatment for osa. the hypothesis is that one night of cpap treatment promotes increased body weight and reduced diuresis in patients with osa. participants will be submitted to 2 consecutive nights of polysomnography (psg). a baseline psg will be performed during the first study visit. during the second study night, participants will be randomized into two groups, cpap and control (repeat baseline psg). overnight urinary volume will be determined. intra and extracellular water volume will be assessed using electrical bioimpedance before bedtime and just after the subject wakes up. plasmatic bnp and adh and urinary osmolality will also be determined during each morning following psg.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of obstructive apnea sleep * over 18 years of age * no previous treatment with continuous positive airway pressure exclusion criteria: * congestive heart failure * renal insufficiency * hepatic failure * urinary incontinency * diuretic therapy

Keywords: obstructive sleep apnea continuous positive airway pressure weight gain
promoting responsible drinking: an internet-based, interactive computer tailored intervention

Conditions: Regular Heavy AOD Use; Excessive Drinking

Summary: excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. this program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults who report non-dependent levels of risky drinking. responsible drinking offers computer-tailored intervention sessions directed at increasing readiness to limit drinking to national guidelines for low-risk drinking and a complementary dynamic web portal providing additional information, activities, and strategies designed to activate and reinforce the change process. the primary objective is to complete and enhance the development of responsible drinking and test it in an effectiveness trial. in phase ii the program capabilities and innovation will expand to integrate the e-health components (cti and e-workbook) with m-health (mobile health) technologies. the e-health components will be enhanced to offer a more interactive and engaging user experience. in addition, m-health technologies (text messaging and mobile device browsing optimization) will be integrated to support engagement in the program and flexible delivery options. 996 employed adults will be recruited to participate in the randomized trial. the treatment group will receive three intervention sessions during the course of six months and group differences on a number of outcomes will be evaluated at 12 and 18 month follow-up assessments.


Eligibility criteria:
inclusion criteria: 1. english speaking 2. 21 years of age or older 3. not enrolled full-time in college 4. employed part or full time 5. not pregnant 6. consumed alcohol in the past 30 days 7. exceeded the niaaa gender-specific low-risk drinking guidelines in the last 30 days 8. not currently interested in or ever having received treatment for substance abuse or dependence 9. not ever having received a physician recommendation to avoid or reduce alcohol use 10. scoring 9 or less on the alcohol use disorders identification test (audit-c).

Keywords: excessive drinking hazardous drinking
to demonstrate the relative bioavailability study of promethazine hcl 50 mg tablets under fasting conditions

Conditions: Allergy

Summary: to demonstrate the relative bioavailability study of promethazine hcl 50 mg tablets under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.

Keywords: antihistamine
clinical assessment of adjunctive omega-3 versus vitamin d daily supplements on active periodontal therapy with stage ii grade b periodontitis patients

Conditions: Vitamin D Deficiency

Summary: clinical assessment of adjunctive omega-3 versus vitamin d daily supplements on active periodontal therapy with stage ii grade b periodontitis patients: a randomized controlled clinical trial.

this randomized clinical trial evaluates the effect of omega- 3 versus vitamin d regarding clinical evaluation 1. clinical attachment loss (cal) 2. probing pocket depth (ppd) 3. modified sulcus bleeding index (msbi)

Eligibility criteria:
inclusion criteria: * • systemic healthy patients * patients aged \> 25 years * patients suffering from stage ii periodontitis with grade b were included in this study, according to 2017 world workshop classification of periodontal disease (papapanou et al. 2017). * patients with interdental clinical attachment loss (cal) of 3-4 mm * no history of previous periodontal therapy. * no taken medications known to interfere healing or periodontal tissue health such as anticonvulsants, calcium channel blockers, or immunosuppressant drugs. * no previous periodontal surgery at involved sites. * good oral hygiene and good compliance with the plaque control instructions following initial therapy. * neither taken antibiotics within the last three months nor nonsteroidal anti-inflammatory drugs within the last three months * absence of diseases or conditions that would interfere with wound healing such as diabetes mellitus or coagulation disorders * absence of oral mucosal inflammatory conditions such as aphthous ulcers or lichen planus. exclusion criteria: * • patients taking omega- 3 or vitamin d as a nutritional supplement were excluded from the study * smoking habits * pregnant and lactating mothers * patients who have been received periodontal surgery in the study area during the last 6 months.